Aspirin therapy for cardiovascular disease

Current Opinion in Hematology

Volumn 3, Issue 5, 1996, Pages 355-360

  Goodnight, Scott H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PROSTAGLANDIN H; THROMBOXANE A2; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART VALVE PROSTHESIS; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STOMACH INJURY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS;

EID: 0029805352     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603050-00004     Document Type: Review

References (49)

1. Vane JR, Flower RJ, Botting RM: History of aspirin and its mechanism of action. Stroke 1990, 21[suppl IV]:IV-12-IV-23.
2. Willard JE, Lange RA, Hillis LD: Current concepts: the use of aspirin in ischemic heart disease. N Engl J Med 1992, 327:175-181.
3. Fuster V, Dyken ML, Vokonas PS, Hennekens C: Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993, 87:659-675.
4. Goodnight SH, Coull BM, McAnulty JH, Taylor LM: Antiplatelet therapy: part 1 & 2. West J Med 1993, 158:385-514.
5. Patrono C: Drug therapy, aspirin as an antiplatelet drug. N Engl J Med 1994, 330:1287-1294.
6. Roth GJ, Calverley DC: Aspirin, platelets, and thrombosis: theory and practice. Blood 1994, 83:885-898.
7. Goodnight SH: Antiplatelet therapy with aspirin: from clinical trials to practice. Thromb Haemost 1995, 74:401-405.
8. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971, 231:232-235.
9. Smith JB, Willis AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971, 231:235-237.
10. Loll PJ, Picot D, Garavito RM: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995, 2:637-643.
11. Allen KN: Aspirin: now we can see it Nature Med 1995, 1:882-883.
12. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991, 325:1137-1141.
13. Mitchell JA, Larkin S, Williams TJ: Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995, 50:1535-1542. A comprehensive review of the action of the two isoforms of cyclooxygenase, COX-1 and COX-2, as they relate to thrombosis, inflammation and toxicity.
14. Kopp E, Ghosh S: Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994, 265:956-959. A provocative paper describing a potential mechanism for the anti-inflammatory action of high-dose aspirin and sodium salicylate via the inhibition of activation of NF-κB, a nuclear transcription factor.
15. Frantz B, O'Neill EA: The effect of sodium salicylate and aspirin on NF-κB. Science 1995, 270:2017-2018.
16. Ghosh S, Kopp E: The effect of sodium salicylate and aspirin on NF-κB: response. Science 1995, 270:2018-2019.
17. Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor-κB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995, 91:1914-1917. This study shows that salicylates (but not other NSAIDs) inhibit NF-κB mobilization, block induction of cell surface adhesion molecules, and inhibit monocyte binding to stimulated endothelial cells.
18. Oeth P, Mackman N: Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood 1995, 86:4144-4152. Another potential link between anti-inflammatory doses of salicylates and atherosclerosis or thrombosis via the suppression of tissue factor synthesis in monocytes.
19. Collins T: Biology of disease. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest 1993, 68:499-508.
20. Buja LM, Willerson JT: Role of inflammation in coronary plaque disruption. Circulation 1994, 89:503-505.
21. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH: The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J 1991, 122:1588-1592.
22. Ranke C, Hecker H, Creutzig A, Alexander K: Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993, 87:1873-1879.
23. Patrono C, Roth GJ: Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? Stroke 1996, 27:756-760. An excellent summary of the current status of the controversy concerning the optimal dose of aspirin for the prevention of stroke and death in patients with ischemic cerebral vascular disease.
24. Underwood MJ, More RS: The aspirin papers. BMJ 1994, 308:71-72.
25. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996, 60:197-199.
26. Barnett HJM, Kaste M, Meldrum H, Eliasziw M: Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts. Stroke 1996, 27:588-592.
27. Barnett HM, Eliasziw M, Meldrum H: Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995, 332:238-248.
28. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25:2331-2336.
29. Helgason CM, Hoff JA, Kondos GT, Brace LD: Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke 1993, 24:1458-1461.
30. Pappas JM, Westengard JC, Bull BS: Population variability in the effect of aspirin on platelet function: implications for clinical trials and therapy. Arch Pathol Lab Med 1994, 118:801-804.
31. Komiya T, Kudo M, Urabe T, Mizuno Y: Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease: assessment by platelet aggregation testing. Stroke 1994, 25:2337-2342.
32. Hart RG, Harrison MJG: Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke 1996, 27:585-587.
33. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G: The relationship among dose, effectiveness, and side effects. Chest 1995, 108:247S-257S. An excellent review of the current status of aspirin as an antithrombotic agent. This is a chapter from the current American College of Chest Physicians Supplement on Antithrombotic Therapy.
34. Goodnight SH: Antiplatelet therapy in cardiovascular disease. In Disorders of Thrombosis, edn 1. Edited by Hull R, Pineo GF. Philadelphia: W.B. Saunders; 1996:31-43.
35. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334:1084-1089. A dramatic effect of combined aspirin and ticlopidine compared with intensive anticoagulant therapy in the prevention of cardiac events and complications following coronary artery stenting.
36. Garcia-Dorado D, Théroux P, Tornos P, Sambola A, Oliveras J, Santos M, Soler JS: Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation 1995, 92:1743-1748. This study suggests that patients who develop acute coronary syndromes despite chronic aspirin use have a reduced severity of thrombotic events.
37. Côté R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, Mackey A, Leclerc J, Mcllraith D, Wadup L, Berger L, et al.: Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Intern Med 1995, 123:649-655.
38. Cairns JA, Markham BA: Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995, 273:965-967.
39. Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994, 154:1443-1448.
40. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K, Kistler P, Kronmal R, Petersen P, Singer D: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
41. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A: Antithrombotic therapy in atrial fibrillation. Chest 1995, 108:352S-359S.
42. Serneri GGN, Modesti PA, Gensini GF, Branzi A, Melandri G, Poggesi L, Rostagno C, Tamburini C, Carnovali M, Magnani B: Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet 1995, 345:1201-1204.
43. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J: Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis. Am Heart J 1995, 130:547-552.
44. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J: A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement N Engl J Med 1993, 329:524-529.
45. Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC: Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost 1992, 68:1-6.
46. Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ: Transdermal modification of platelet function: a dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 1993, 88:556-561.
47. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G: Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995, 96:2711-2718. A new and innovative formulation of aspirin in which a nitric oxide moiety has been linked to aspirin in an attempt to increase its antithrombotic effects and to decrease toxicity.
48. Mousa SA, DeGrado WF, Mu DX, Kapil RP, Lucchesi BR, Reilly TM: Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist Circulation 1996, 93:537-543.
49. Verstraete M, Zoldhelyi P: Novel antithrombotic drugs in development Drugs 1995, 49:856-884.